Results 121 to 130 of about 8,893 (235)

Diabetes management in maternally inherited diabetes and deafness (MIDD): A review and a proposed treatment algorithm

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 826-839, February 2026.
Abstract Maternally inherited diabetes and deafness (MIDD) is a mitochondrial disorder usually caused by the variant m.3243A>G in the MT‐TL1 gene. We have proposed that diabetes in MIDD arises from a combination of insulin resistance and impaired β‐cell function that is more likely to occur in the presence of high skeletal muscle heteroplasmy and ...
Ahsen Chaudhry, David M. Thompson, Jean‐Pierre Chanoine   +2 more
wiley   +1 more source

Additive effects of GLY-200 (oral pharmacologic duodenal exclusion therapy) and GLP-1R agonist in obesity management

Molecular Metabolism
Type 2 diabetes and obesity impact billions of people and the global prevalence is only growing. Current treatment options, which include pharmacotherapy, e.g., GLP-1 receptor agonists (GLP-1RA) and bariatric surgical approaches have limitations. GLY-200
Taylor L. Carlson, Mark Fineman, Stace Kernodle, Chelsea R. Hutch, Christine Bryant, Kevin Colbert, Randy J. Seeley, Ashish Nimgaonkar   +7 more
doaj   +1 more source

Real‐world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 895-905, February 2026.
Abstract Aim A retrospective observational cohort study, in the Netherlands, evaluated clinical outcomes with oral semaglutide. Methods Glucagon‐like peptide‐1 receptor agonists (GLP‐1ra) naïve type 2 diabetes (T2D) patients who initiated oral semaglutide between 1 January 2020 and 31 December 2022 were identified from the PHARMO Data Network.
Abigail Postema, Jordy Gaspersz, Brenda N. Baak, Eline L. Huisman, Charlotte Hoogstraten, Lise Meinicke Hagelund, Fernie J. A. Penning‐van Beest, Jetty A. Overbeek   +7 more
wiley   +1 more source

Promising results but caution needed in GLP-1RA large scale epidemiology

Trends in Endocrinology & Metabolism
Investigating the association between glucagon-like peptide 1 receptor agonists (GLP1-RAs) and incident disease across 175 health outcomes in US Veterans with diabetes, Xie et al. recently reported lower risk for cardiokidney disease and substance use disorders, but higher risk for pancreatitis, gastrointestinal disorders, and arthritis.
Salil V. Deo, Naveed A. Sattar
openaire   +2 more sources

One‐year usage patterns of SGLT‐2 inhibitors and GLP‐1 receptor agonists in individuals with type 2 diabetes in a real‐world population

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 972-981, February 2026.
Abstract Aims Real‐world studies of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) typically assess adherence and discontinuation as separate outcomes. We applied a novel approach that integrates these measures to categorize patterns of drug usage.
Louise A. Donnelly, Katyayeni Singh, Rory J. McCrimmon, Ewan R. Pearson   +3 more
wiley   +1 more source

Ethnic differences in the comparative effectiveness of second‐line type 2 diabetes medications in preventing cardiovascular disease

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1013-1023, February 2026.
Abstract Aim To investigate ethnic differences in the comparative effectiveness of sulfonylureas (SU), dipeptidyl peptidase‐4 inhibitors (DPP4i) and sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) on cardiovascular outcomes. Materials and Methods We identified adults with type 2 diabetes in UK electronic health records initiating SU, DPP4i or SGLT2i
Mia Harley, Christopher T. Rentsch, Elizabeth Williamson, Anoop S. V. Shah, Patrick Bidulka, Charlotte Warren‐Gash, Marleen Bokern, Rohini Mathur   +7 more
wiley   +1 more source

Risk of Phimosis Associated with SGLT2i versus GLP-1RA: A Danish Cohort Study

Diabetes Care
<p dir="ltr"><b>Objective</b></p><p dir="ltr">Sodium-glucose cotransporter 2 inhibitors (SGLT2is) induce glucosuria, potentially leading to infection and inflammation in the preputial microenvironment, subsequently increasing the risk of phimosis.
Christine Ljungberg, Mette Nørgaard, Christina Vandenbroucke-Grauls, Jakob Kristian Jakobsen, Morten Haaning Charles, Anton Pottegård, Michael Dalager-Pedersen, Henrik Toft Sørensen, Reimar Wernich Thomsen   +8 more
openaire   +2 more sources

The value and impact of weight reduction from the perspective of people with type 2 diabetes in the United States

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1116-1125, February 2026.
Abstract Aims To understand the importance and potential impacts of reaching a lower weight or body mass index (BMI) from the perspectives of people with type 2 diabetes (T2D) across BMI levels. Materials and methods A cross‐sectional survey, informed by qualitative interviews, was administered to a sample representative of the US T2D population by BMI.
Melissa M. Ross, Sarah Mulnick, Kristina S. Boye, Ashley Samuelson, Vivian Thuyanh Thieu, Christine Longuet, Jennifer Glass, Meredith M. Hoog   +7 more
wiley   +1 more source

Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia

Aim: Sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve glycaemic control and cardio-renal outcomes for people with type 2 diabetes (T2D).
Day, RO , de Oliveira Costa, J , Falster, MO , Greenfield, JR , Havard, A , Lin, J , Milder, TY , Neuen, BL , Pearson, SA , Stocker, SL   +9 more
core   +1 more source

Sex differences in the weight response to GLP-1RA in people with type 2 diabetes. A long-term longitudinal real-world study [PDF]

Sex differences may influence pathophysiology, treatment response, and outcomes of type 2 diabetes (T2D). We assessed whether sex affected clinical response to GLP-1 receptor agonists (GLP-1RA) in a large real-world cohort.
Avogaro A., Cignarella A., Consoli A., Fadini G. P., Leonetti F., Marassi M., Marzullo P., Nollino L., Russo G. T., Strazzabosco M.   +9 more
core   +1 more source